Day: May 6, 2020

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 06, 2020 (GLOBE NEWSWIRE) — CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced the expansion of its Senior Leadership Team with the appointment of Angelos Baxevanis as Senior Vice President Communication and Marketing. With nearly two decades of experience in the field, Angelos will have the overall responsibility of further developing the marketing and communication strategies, establishing internal marketing workflows, and further positioning CENTOGENE as a leading provider of medical solutions for rare disease patients.Prof. Arndt Rolfs, CEO of the Company, stated, “We are extremely pleased to welcome...

Coloplast delivered 9% organic growth and EBIT increased by 15% to DKK 1,542m, corresponding to an EBIT margin of 32%, in the second quarter of the 2019/20 financial year. The company maintains its financial guidance for 2019/20.EBIT in the second quarter amounted to DKK 1,542m, a 15% increase, corresponding to an EBIT-margin of 32% against 30% last year. ROIC after tax and before special items in the second quarter was 46% against 44% last year.“In these extraordinary times, our priorities at Coloplast are clear. We want to keep our employees safe, while continuing to serve our customers. Our customers rely on our help and support, so they can continue to manage their conditions. We have implemented a multitude of new guidelines and safety measures across our company to ensure a safe and stable supply of products for users and healthcare...

Coloplast leverede en organisk vækst på 9% og en forbedring af driftsresultatet med 15% til 1.542 mio. kr., svarende til en overskudsgrad på 32%, i andet kvartal af regnskabsåret 2019/20. Selskabet fastholder sine finansielle forventninger til 2019/20.Driftsresultatet (EBIT) steg i andet kvartal med 15% i danske kroner til 1.542 mio. kr., svarende til en overskudsgrad på 32% mod 30% i samme periode året før. Afkastet af den investerede kapital (ROIC) efter skat og før særlige poster blev 46% i andet kvartal mod 44% året før.“I disse ekstraordinære tider er vores prioriteter klare. Vi vil beskytte vores medarbejdere, samtidig med at vi betjener vores kunder. Vores kunder er afhængige af vores hjælp og støtte, så de fortsat kan håndtere deres kroniske lidelser. Vi har implementeret en lang række nye retningslinjer og sikkerhedsforanstaltninger...

H1 2019/20Interim financial report, H1 2019/20(01 October 2019 – 31 March 2020)            Solid performance continues in Q2 impacted by COVID-19 outbreak and stock building in primarily Europe, guidance for 2019/20 maintainedColoplast delivered 9% organic growth in the second quarter. Reported revenue in DKK was up by 10% to DKK 4,823m. Year to date organic growth was 8% and reported revenue in DKK was up by 9% to DKK 9,535m.Organic growth rates by business area year to date: Ostomy Care 9%, Continence Care 9%, Interventional Urology 6% and Wound & Skin Care 7%.During the COVID-19 outbreak, the health and safety of the company’s employees and continuity of service to customers continue to be the key priority. Coloplast’s global production and distribution sites continue to operate at normal levels and the company is able to...

H1 2019/20Regnskabsmeddelelse, 1. halvår 2019/20(1. oktober 2019 – 31. marts 2020)Fortsat solid udvikling i et andet kvartal som var påvirket af udbruddet af COVID-19 og lageropbygning hovedsageligt i Europa. Uændrede forventninger til 2019/20Coloplast leverede en organisk omsætningsvækst på 9% i andet kvartal. Den rapporterede omsætning, målt i danske kroner, steg med 10% til 4.823 mio. kr. I første halvår blev den organiske omsætningsvækst 8% og det rapporterede salg, målt i danske kroner, steg 9% til 9.535 mio. kr.I forretningsområderne blev den organiske vækst for årets første seks måneder henholdsvis 9% i Stomi, 9% i Kontinens, 6% i Urologi og 7% i Hud- og Sårpleje.I lyset af udbruddet af COVID-19 er vores førsteprioritet fortsat medarbejdernes helbred og sikkerhed samt den fortsatte servicering af kunderne. Coloplasts globale...

TORONTO, May 06, 2020 (GLOBE NEWSWIRE) — Torex Gold Resources Inc. (the “Company” or “Torex”) (TSX: TXG) reports the Company’s financial and operating results for the three months ended March 31, 2020.Fred Stanford, President & CEO of Torex, stated:“Operationally this was a solid quarter, with 108,537 gold ounces produced. The production performance was complemented by the continued outstanding safety performance. As of the end of March, the team had worked over 5.5 million hours without a lost time injury. Since then, the lost time injury free record has been extended to over 6 million hours and more than one year worked. This commitment to safe work practices has been expanded to healthy work practices as well. To date, we have had no known or suspected cases of COVID-19 at our operation.“Cost control was successful, with...

VANCOUVER, British Columbia, May 06, 2020 (GLOBE NEWSWIRE) — NuLegacy Gold (TSXV: NUG; OTCQB: NULG.F) is pleased to welcome Metalla Royalty & Streaming Ltd. (“Metalla”) as a new stakeholder in NuLegacy’s 108 square kilometer flagship Red Hill property in the heart of Cortez gold trend of North-Central Nevada.Metalla has announced the purchase (detailed below) of one half of the 3% gross overriding royalty (GOR) currently held by Idaho Resources Corporation (“IRC”)[*] on NuLegacy’s Red Hill property to close June 1, 2020.Valuing GORs is a complicated business made easier in this instance by the straightforward nature of the purchase price for IRC; thus prorating the US$4 million purchase price for the total of 2% GOR purchased (1.5% GOR on Red Hill and 0.5% GOR on Anglo/Zeke claims) values a 1% GOR in the Red Hill project at...

ST. JOHN’S, Newfoundland and Labrador, May 06, 2020 (GLOBE NEWSWIRE) — Fortis Inc. (“Fortis” or the “Corporation”) (TSX/NYSE: FTS), a well-diversified leader in the North American regulated electric and gas utility industry, released its first quarter results today.HighlightsFortis continues to provide safe, reliable service during the COVID-19 pandemicFirst quarter 2020 net earnings were $312 million, or $0.67 per common shareStrong rate base growth during the quarter was tempered by delayed rates and charges associated with financial market volatility in ArizonaCapital expenditures of $1.2 billion, representing 28% of the 2020 capital plan, were completed during the first quarterThe Corporation’s five-year capital plan of $18.8 billion and dividend growth guidance remain unchanged“The...

First Quarter 2020 Results and Financial HighlightsRevenues of $60.0 million; down 2% year over yearNon-GAAP EPS of $0.14; GAAP EPS of $0.05Net cash provided by operating activities of $21 million for the first quarter, and $50 million for the last twelve monthsTotal deferred revenue, as defined by the company, balance of $181 million, up 14% from last yearTEL AVIV, Israel, May 06, 2020 (GLOBE NEWSWIRE) — Radware® (NASDAQ: RDWR), a leading provider of cyber security and application delivery solutions, today announced its consolidated financial results for the quarter ended March 31, 2020.“Radware entered the COVID-19 crisis in a strong position, and continues to execute on its strategy and pursue its long-term goals through it,“ said Roy Zisapel, Radware’s President & CEO. “Our performance in the first quarter reflects solid...

NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the first patients have been dosed in the 300-patient randomized placebo-controlled Phase 2/3 trial in the United States of Mesoblast’s allogeneic cellular medicine remestemcel-L in COVID-19 infected patients with moderate to severe acute respiratory distress syndrome (ARDS) on ventilator support.Mesoblast holds an Investigational New Drug (IND) application cleared by the FDA for use of remestemcel-L in the treatment of patients with COVID-19 ARDS. The clinical protocol for the Phase 2/3 trial is based on initial promising results from use of remestemcel-L in patients with moderate to severe COVID-19 ARDS under an emergency IND application or expanded access protocol...